Scalper1 News
Big-cap biotech Biogen Idec (BIIB) soundly beat analysts’ Q2 expectations and substantially raised its guidance early Wednesday, sending shares up more than 11% in midday trading in the stock market today to near 338, a four-month high. Biogen’s Q2 earnings rose 52% over the year-earlier quarter to $3.49 a share, topping analysts’ consensus by 66 cents. Sales increased 40% to $2.4 billion vs. the Street’s $2.16 billion. The company increased its Scalper1 News
Scalper1 News